Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model.
Animals
Mice
Cuprizone
/ toxicity
Cytokines
/ metabolism
Demyelinating Diseases
/ pathology
Disease Models, Animal
Membrane Glycoproteins
/ genetics
Mice, Inbred C57BL
Mice, Knockout
Microglia
/ metabolism
Models, Genetic
Myelin Sheath
/ metabolism
Neuroinflammatory Diseases
Receptors, Immunologic
/ genetics
Cuprizone
MRI
Microglia
Neuroinflammation
Phagocytosis
TREM2
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
08 Feb 2023
08 Feb 2023
Historique:
received:
13
07
2022
accepted:
12
12
2022
entrez:
9
2
2023
pubmed:
10
2
2023
medline:
11
2
2023
Statut:
epublish
Résumé
Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell-surface immunoreceptor expressed on microglia, osteoclasts, dendritic cells and macrophages. Heterozygous loss-of-function mutations in TREM2, including mutations enhancing shedding form the cell surface, have been associated with myelin/neuronal loss and neuroinflammation in neurodegenerative diseases, such as Alzheimer`s disease and Frontotemporal Dementia. Using the cuprizone model, we investigated the involvement of soluble and cleavage-reduced TREM2 on central myelination processes in cleavage-reduced (TREM2-IPD), soluble-only (TREM2-sol), knockout (TREM2-KO) and wild-type (WT) mice. The TREM2-sol mouse is a new model with selective elimination of plasma membrane TREM2 and a reduced expression of soluble TREM2. In the acute cuprizone model demyelination and remyelination events were reflected by a T2-weighted signal intensity change in magnetic resonance imaging (MRI), most prominently in the external capsule (EC). In contrast to WT and TREM2-IPD, TREM2-sol and TREM2-KO showed an additional increase in MRI signal during the recovery phase. Histological analyses of TREM2-IPD animals revealed no recovery of neuroinflammation as well as of the lysosomal marker LAMP-1 and displayed enhanced cytokine/chemokine levels in the brain. TREM2-sol and, to a much lesser extent, TREM2-KO, however, despite presenting reduced levels of some cytokines/chemokines, showed persistent microgliosis and astrocytosis during recovery, with both homeostatic (TMEM119) as well as activated (LAMP-1) microglia markers increased. This was accompanied, specifically in the EC, by no myelin recovery, with appearance of myelin debris and axonal pathology, while oligodendrocytes recovered. In the chronic model consisting of 12-week cuprizone administration followed by 3-week recovery TREM2-IPD displayed sustained microgliosis and enhanced remyelination in the recovery phase. Taken together, our data suggest that sustained microglia activation led to increased remyelination, whereas microglia without plasma membrane TREM2 and only soluble TREM2 had reduced phagocytic activity despite efficient lysosomal function, as observed in bone marrow-derived macrophages, leading to a dysfunctional phenotype with improper myelin debris removal, lack of remyelination and axonal pathology following cuprizone intoxication.
Identifiants
pubmed: 36755323
doi: 10.1186/s12974-022-02671-z
pii: 10.1186/s12974-022-02671-z
pmc: PMC9909920
doi:
Substances chimiques
Cuprizone
5N16U7E0AO
Cytokines
0
Membrane Glycoproteins
0
Receptors, Immunologic
0
Trem2 protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Informations de copyright
© 2023. The Author(s).
Références
J Exp Med. 2021 Oct 4;218(10):
pubmed: 34424266
Front Immunol. 2020 Nov 06;11:588021
pubmed: 33240276
Nature. 2019 Feb;566(7745):543-547
pubmed: 30747918
J Exp Med. 2015 Mar 9;212(3):287-95
pubmed: 25732305
Bioinformatics. 2011 Nov 1;27(21):2987-93
pubmed: 21903627
J Mol Neurosci. 2013 Oct;51(2):567-72
pubmed: 23666824
Nat Commun. 2020 Oct 23;11(1):5370
pubmed: 33097708
Neuron. 2021 Apr 21;109(8):1283-1301.e6
pubmed: 33675684
J Exp Med. 2020 Sep 7;217(9):
pubmed: 32579671
Nat Biotechnol. 2014 Oct;32(10):1019-25
pubmed: 25129690
Front Cell Neurosci. 2022 Feb 07;16:816439
pubmed: 35197828
Acta Neuropathol. 2022 Feb;143(2):125-141
pubmed: 34878590
Mol Neurodegener. 2019 May 8;14(1):18
pubmed: 31068200
J Neurosci Res. 2010 Jun;88(8):1632-44
pubmed: 20091773
Acta Neuropathol. 2015 Mar;129(3):429-47
pubmed: 25631124
Acta Neuropathol Commun. 2018 Feb 15;6(1):9
pubmed: 29448957
Acta Neuropathol. 2017 Sep;134(3):441-458
pubmed: 28685323
Cell. 2017 Jun 15;169(7):1276-1290.e17
pubmed: 28602351
Glia. 2016 Dec;64(12):2104-2119
pubmed: 27535761
FASEB J. 2019 Sep;33(9):10425-10442
pubmed: 31219699
Drug Metab Dispos. 2007 Oct;35(10):1916-25
pubmed: 17656469
J Neurosci. 2010 Dec 15;30(50):17091-101
pubmed: 21159979
J Comp Neurol. 2006 Dec 1;499(4):565-82
pubmed: 17029271
J Leukoc Biol. 2021 Nov;110(5):829-837
pubmed: 34061398
Cell. 2015 Mar 12;160(6):1061-71
pubmed: 25728668
Immunity. 2019 Jan 15;50(1):253-271.e6
pubmed: 30471926
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Neurobiol Aging. 2017 May;53:194.e13-194.e22
pubmed: 28214109
J Alzheimers Dis Parkinsonism. 2014 Nov;4(5):
pubmed: 25664220
Brain. 2017 Feb;140(2):399-413
pubmed: 28007993
Sci Transl Med. 2019 Aug 28;11(507):
pubmed: 31462511
Cell Rep. 2022 May 31;39(9):110883
pubmed: 35649351
Front Immunol. 2021 Mar 25;12:633796
pubmed: 33841415
Mol Neurodegener. 2017 Aug 2;12(1):56
pubmed: 28768545
PLoS One. 2016 Apr 07;11(4):e0152480
pubmed: 27054832
Cell. 2017 Aug 10;170(4):649-663.e13
pubmed: 28802038
Nature. 2019 Feb;566(7745):538-542
pubmed: 30675058
Neurosci Lett. 2017 Nov 1;660:109-114
pubmed: 28923481
Magn Reson Med. 1986 Dec;3(6):823-33
pubmed: 3821461
Acta Neurol Scand Suppl. 2008;188:72-6
pubmed: 18439226
Acta Neuropathol. 2009 Dec;118(6):723-36
pubmed: 19763593
Neuron. 2021 Apr 7;109(7):1100-1117.e10
pubmed: 33606969
Nat Neurosci. 2021 Apr;24(4):489-503
pubmed: 33603230
Neuron. 2020 Mar 4;105(5):837-854.e9
pubmed: 31902528
Front Cell Neurosci. 2014 Mar 13;8:73
pubmed: 24659953
Brain. 2013 Jan;136(Pt 1):147-67
pubmed: 23266461
EMBO Mol Med. 2020 Apr 7;12(4):e11227
pubmed: 32154671
Nat Rev Neurol. 2019 Aug;15(8):447-458
pubmed: 31256193
Mol Neurodegener. 2018 May 21;13(1):24
pubmed: 29784049
FEBS Lett. 2017 Mar;591(5):774-783
pubmed: 28186340
Mol Neurodegener. 2016 Jan 12;11:3
pubmed: 26754172
EMBO Mol Med. 2017 Oct;9(10):1366-1378
pubmed: 28855301
Acta Neuropathol. 2020 Oct;140(4):513-534
pubmed: 32772264
J Exp Med. 2015 Apr 6;212(4):481-95
pubmed: 25779633
Neurobiol Dis. 2022 Apr;165:105630
pubmed: 35041990
Nat Neurosci. 2019 Jul;22(7):1046-1052
pubmed: 31182869
J Clin Invest. 2015 May;125(5):2161-70
pubmed: 25893602
Cell Rep. 2020 Feb 4;30(5):1271-1281
pubmed: 32023447
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Radiology. 1986 Aug;160(2):537-41
pubmed: 3523597
Biomark Med. 2012 Aug;6(4):441-54
pubmed: 22917146
Sci Adv. 2021 Dec 10;7(50):eabk1131
pubmed: 34890221
J Exp Med. 2017 Mar 6;214(3):597-607
pubmed: 28209725
Nat Commun. 2019 Mar 25;10(1):1365
pubmed: 30911003
Neuroimage. 2012 Jan 16;59(2):1028-36
pubmed: 21945466